首頁 > 市場調查報告書 > 醫療設備

e保健區塊鏈

市場調查報告書

商品編碼

1629892

藥品供應鏈管理市場的全球區塊鏈 - 2025-2033

Global Blockchain in Pharmaceutical Supply Chain Management Market - 2025-2033

出版日期: 2024年12月30日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球區塊鏈醫藥供應鏈管理市場規模達12.7億美元，預計2033年將達到65.7億美元，2025-2033年預測期間複合年成長率為21.5%。

區塊鏈是一種去中心化的分散式帳本技術，可以安全地記錄眾多電腦之間的交易。在藥品供應鏈的背景下，它維護著涉及藥品的每筆交易（從生產到分銷到最終用戶）的不可變且透明的記錄。該系統允許所有利害關係人、製造商、分銷商、藥房和監管機構存取有關藥品狀態和有效性的即時資料。區塊鏈的加密性質可以保護敏感資料免遭未經授權的存取和操縱。區塊鏈透過智慧合約實現活動自動化，可以簡化營運、最大限度地降低管理成本並縮短供應鏈時間。

資料安全性、透明度和可追溯性的提高是預測期內推動市場的促進因素。為了解決假藥數量增加的嚴重問題，推出了藥品追溯服務。例如，2024 年 11 月，埃塞俄比亞食品藥物管理局 (EFDA) 和 Medical Value Chain 宣佈建立戰略合作夥伴關係，以實施尖端的基於區塊鏈的藥品追蹤系統。這有助於打擊假藥並確保安全性和真實性。

市場動態：

驅動程式和限制

提高安全性、透明度和可追溯性

資料安全性、透明度和可追溯性的提高預計將成為全球區塊鏈在藥品供應鏈管理市場成長的重要因素。隨著製藥業面臨假藥、資料外洩和監管合規等挑戰，區塊鏈作為一種革命性的方法出現，可以有效解決這些關鍵問題。

提高資料安全性是區塊鏈技術最吸引人的好處之一。區塊鏈使用去中心化且不可變的分類帳來確保所有交易記錄都被安全存儲，並且在沒有有效授權的情況下不能被編輯或銷毀。此功能逐漸降低了資料外洩和操縱的可能性，這在舊的集中式系統中很常見。近年來，資料外洩事件屢屢發生。例如，2023 年，超過 540 個組織和 1.12 億個人涉及向 HHS 民權辦公室 (OCR) 報告的醫療保健資料外洩事件，而 2022 年有 590 個組織和 4,860 萬受影響個人。資料到 2022 年，將有超過 100 萬筆記錄被洩露，另外還有 14 起資料外洩事件，超過 50 萬筆記錄。區塊鏈技術在資料安全方面發揮著至關重要的作用。

全球假藥數量不斷增加是促進因素之一，需要藥品追溯服務來克服假藥的生產。例如，根據輝瑞公司發表的一篇文章，至少有 104 種輝瑞藥品已在超過 116 個國家被證實有仿冒版。據藥品安全研究所 (PSI) 稱，2023 年，執法官員在 142 個國家發現了 6,897 起藥品假冒、非法轉移和竊盜事件。 2023 年，PSI 記錄了 4,894 人因藥物犯罪被捕，這是連續 22 年資料中逮捕人數最多的一次。因此，越來越多的資料外洩和假藥的生產增加了藥品供應鏈管理市場對區塊鏈的需求。

初期投資高

高初始投資等因素預計將阻礙全球區塊鏈在醫藥供應鏈管理市場的發展。實施區塊鏈解決方案需要大量的前期支出，包括對技術基礎設施、軟體開發和員工培訓的投資。組織必須購買適當的技術和軟體來實現區塊鏈操作，這可能是一項重大成本。此外，建立和管理這些系統所需的專業技能也推高了價格。許多企業可能很難證明這些費用的合理性，特別是當投資回報 (ROI) 並不立即明顯時。這種猶豫可能會阻礙區塊鏈技術在醫藥供應鏈中的全面採用。

Blockchain is a decentralized, distributed ledger technology that securely records transactions between numerous computers. In the context of pharmaceutical supply chains, it maintains an immutable and transparent record of every transaction involving pharmaceutical products, from production to distribution to end users. This system allows all stakeholders, manufacturers, distributors, pharmacies, and regulators to access real-time data about the status and validity of pharmaceuticals. The cryptographic nature of blockchain safeguards sensitive data from unauthorized access and manipulation. Blockchain, by automating activities via smart contracts, can streamline operations, minimize administrative costs, and enhance supply chain timelines.

The improved data security, transparency, and traceability is the driving factor that drives the market over the forecast period. To address critical concerns about increasing the number of counterfeit pharmaceuticals, drug traceability services are launched. For instance, in November 2024, the Ethiopia Food and Drug Authority (EFDA), and Medical Value Chain announced strategic partnerships to implement cutting-edge blockchain-enabled pharmaceutical track and track system. This helps in combating counterfeit medicines and ensuring safety, authenticity.

Market Dynamics: Drivers & Restraints

Improved security, transparency, and traceability

Improved data security, transparency, and traceability is expected to be a significant factor in the growth of the global blockchain in the pharmaceutical supply chain management market. As the pharmaceutical industry faces challenges such as counterfeit pharmaceuticals, data breaches, and regulatory compliance, blockchain emerges as a revolutionary approach that effectively addresses these critical concerns.

Improved data security is one of the most appealing benefits of blockchain technology. Blockchain uses a decentralized and immutable ledger to ensure that all transaction records are securely stored and cannot be edited or destroyed without valid authority. This feature gradually decreases the likelihood of data breaches and manipulation, which are common in older centralized systems. In recent times, there have been many data breaches. For instance, in 2023, more than 540 organizations and 112 million individuals were implicated in healthcare data breaches reported to the HHS Office for Civil Rights (OCR), compared to 590 organizations and 48.6 million impacted individuals in 2022. There were 11 reported healthcare data breaches of more than 1 million records in 2022 and a further 14 data breaches of over 500,000 records. Blockchain technology plays a crucial role in data security.

The increasing number of counterfeit pharmaceuticals across the globe is one of the driving factors and it needs drug traceability services to overcome the production of counterfeit pharmaceuticals. For instance, according to an article published by Pfizer, counterfeit versions of at least 104 Pfizer medicines have been confirmed in more than 116 countries. According to the Pharmaceutical Security Institute (PSI), law enforcement officials uncovered 6,897 incidents of counterfeiting, illegal diversion, and theft of pharmaceuticals in 142 countries in 2023. The crimes involved more than 2,440 different medicines across every therapeutic category. The PSI documented 4,894 arrests for pharmaceutical crime in 2023, the largest number of arrests achieved in 22 consecutive years of data. So, the increasing number of data breaches and the production of counterfeit pharmaceuticals increase the demand for the blockchain in the pharmaceutical supply chain management market.

High initial investment

Factors such as high initial investment are expected to hamper the global blockchain in pharmaceutical supply chain management market. Implementing blockchain solutions incurs significant upfront expenditures, including investments in technical infrastructure, software development, and employee training. Organizations must purchase the appropriate technology and software to enable blockchain operations, which can be a major cost. Furthermore, the necessity for specialized skills to build and administer these systems drives up prices. Many businesses may struggle to justify these charges, particularly when the return on investment (ROI) is not immediately obvious. This hesitation may hinder the overall adoption of blockchain technology in the pharmaceutical supply chain.

Segment Analysis

The global blockchain in the pharmaceutical supply chain management market is segmented based on offerings, application, type, end-user, and region.

Drug traceability segment is expected to dominate the global blockchain in pharmaceutical supply chain management market share

The drug traceability segment is the most dominant due to its critical role in enhancing safety, compliance, and operational efficiency within the pharmaceutical industry. As the threat of counterfeit drugs grows, stakeholders recognize the importance of strong traceability systems that can ensure the authenticity and integrity of pharmaceutical products throughout their lifecycle. Drug traceability is the process of tracking pharmaceuticals from their point of manufacture to the final consumer. This procedure is critical for preventing counterfeit pharmaceuticals from entering the supply chain, which poses serious threats to patient safety and public health. Blockchain technology provides a decentralized, immutable database that records all drug-related transactions, creating a transparent and traceable history. This feature not only aids in the detection and elimination of counterfeit products but also assures compliance with regulatory standards requiring strict pharmaceutical tracking.

The number of counterfeit pharmaceuticals is increasing day by day. The increase in the number of counterfeit pharmaceuticals increases the demand for drug traceability services. For instance, according to the World Health Organization, at least 1 in 10 medicines in low- and middle-income countries are substandard or falsified. Countries spend an estimated US$ 30.5 billion per year on substandard and falsified medical products. Substandard and falsified medical products are often sold online or in informal markets. Moreover, according to the National Institute of Health, it has been estimated that up to 15% of all sold drugs are fake, and in parts of Africa and Asia this figure exceeds 50%. The FDA estimates that fake drugs comprise approximately 10% of the global medicine market. The number of investigations of possible counterfeit drugs by the FDA has jumped from about five per year in the 1990s to more than 20 per year since 2000.

There are recent launches of blockchain-based drug traceability services. For instance, in May 2024, Merck, a leading scientific and technological firm, introduced the M-Trace Software & Mobile App, a comprehensive data tracking solution for digitizing sterility testing. The software improves overall process safety by automatically documenting data at each stage of the testing process. This decreases the chances of divergence, false positive results, and human error. The increasing number of counterfeit pharmaceuticals and recent launches of blockchain-based drug traceability services drive the market of this segment making the drug traceability segment a dominant one.

Geographical Analysis

North America is expected to hold a significant position in the global blockchain in pharmaceutical supply chain management market share

The blockchain in the pharmaceutical supply chain management market in the North American Region is driven by several key factors that underscore its robust industrial landscape and consumer demand, increasing number of cybercrimes, strong regulatory support, and increasing awareness of the benefits of blockchain technology and increased number of launches.

In recent times, there have been launches of blockchain services in this region. For instance, in May 2023, Patientory Inc., the creator of a blockchain-based, HIPAA-compliant, private medical data ecosystem, announced today that it has launched two solutions, Patientory Consumer Decentralized Application-designed to help patients more efficiently and securely store and earn money from their medical data and Neith Enterprise Dashboard in partnership with Prosper Healthtech, a community-backed organization committed to equity in Birmingham offering a supportive network of organizations throughout the city, including UAB Hospital, PackHealth, and Blue Cross Blue Shield.

The increasing number of cybercrimes is one of the major drivers in this region. The cybercrimes can be reduced by storing the systems securely using software blockchain services. For instance, according to an article posted by Palo Alto Networks in January 2024, Malicious attacks on healthcare have grown exponentially in recent years. According to the HHS Office for Civil Rights (OCR), large breaches increased by 93% between 2018 and 2023. Additionally, large breaches involving ransomware increased by 278%.

The increase in the number of counterfeit pharmaceuticals in this region increases the demand for global blockchain in pharmaceutical supply chain management which helps in the marketing of original products. For instance, in January 2024, the FDA alerted healthcare professionals and consumers that unsafe counterfeit versions of Botox (botulinum toxin) have been found in multiple states and administered to consumers for cosmetic purposes. Moreover, in December 2023, the FDA investigated and announced that a counterfeit Ozempic (semaglutide) injection of 1 milligram (mg) was found and the U.S. drug supply chain seized thousands of units of the product. All these factors make North America hold the highest market share.

Asia Pacific is growing at the fastest pace in the global blockchain in pharmaceutical supply chain management market

Asia Pacific's rapid growth in the Global Blockchain in Pharmaceutical Supply Chain Management Market is driven by a combination of factors including the booming e-commerce sector, increasing industrialization, proactive technology adoption, increasing number of counterfeit versions, and supportive government initiatives. The Asia Pacific area is rapidly industrializing, resulting in rising consumer markets that require improved supply chain visibility and efficiency. Countries like as China, India, and Japan are at the forefront of using blockchain technology to simplify processes and combat counterfeit products.

The rapid expansion of the e-commerce sector is a major driver of blockchain implementation in the Asia Pacific pharmaceutical supply chain. As e-commerce grows more popular, there is a greater demand for efficient and transparent supply chain solutions that guarantee timely delivery and product authenticity. Blockchain technology provides a reliable foundation for tracking pharmaceuticals along the supply chain, giving stakeholders real-time visibility into product movements.

Competitive Landscape

The major global players in the global blockchain in pharmaceutical supply chain management market include IBM, Microsoft, SAP SE, Oracle, Cloud Software Group, Inc., Auxesis Infotech Pvt. Ltd., Omnichain Solutions, Walmart Inc., FarmaTrust, Amazon Web Services, Inc. among others.

Emerging Players

VeChain, Modum, and Everledger among others

Key Developments

In September 2023, the Republic of Mauritius launched a blockchain-based eVerify service. E-Verify is a system that uses blockchain to verify and authenticate information or transactions electronically. Emerging technologies such as blockchain, big data, Artificial Intelligence, and the internet create new ways for consumers to interact while disrupting traditional business models.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global blockchain in pharmaceutical supply chain management market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Offerings
3.2. Snippet by Application
3.3. Snippet by Type
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. Improved Data Security, Transparency, And Traceability
- 4.1.3. Restraints
- 4.1.4. High Initial Investment
- 4.1.5. Opportunity
- 4.1.6. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Offerings

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offerings
- 6.1.2. Market Attractiveness Index, By Offerings
6.2. Platform*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Service

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Drug Traceability*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Inventory Monitoring
7.4. Smart Contracts
7.5. Compliance Management
7.6. Payment & Settlement
7.7. Others

8. By Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.1.2. Market Attractiveness Index, By Type
8.2. Private Blockchain*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Public Blockchain
8.4. Hybrid Blockchain

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Manufacturers*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Distributors
9.4. Healthcare Providers

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. The U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. UK
  - 10.3.7.3. France
  - 10.3.7.4. Italy
  - 10.3.7.5. Spain
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
  - 10.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
  - 10.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  - 10.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  - 10.6.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. IBM*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Microsoft
12.3. SAP SE
12.4. Oracle
12.5. Cloud Software Group, Inc.
12.6. Auxesis Infotech Pvt. Ltd.
12.7. Omnichain Solutions
12.8. Walmart Inc.
12.9. FarmaTrust
12.10. Amazon Web Services, Inc.

LIST NOT EXHAUSTIVE